Supplementary Information for
“Integrated analyses prioritize therapies for PIK3CA-mutant breast cancer and reveal a pro-survival role for p21 in drug resistance”
Hon Yan Kelvin Yip1,2, Sung-Young Shin1,2, Annabel Chee1,3, Ching-Seng Ang4, Fernando Rossello5, Lee Hwa Wong1, Lan K. Nguyen1,*, and Antonella Papa1,6,* 
1Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria 3800, Australia.
4Bio21 Mass Spectrometry and Proteomics Facility, The University of Melbourne, Parkville, VIC 3010, Australia.
5 Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
2These authors contributed equally.
3Present address: Centre for Muscle Research, Department of Anatomy and Physiology, The University of Melbourne, Melbourne, VIC 3010, Australia
6Lead contact
*Corresponding author: lan.k.nguyen@monash.edu (L.K.N), antonella.papa@monash.edu (A.P.)
